In a report released today, Donald Hooker from KeyBanc maintained a Buy rating on Evolent Health (NYSE: EVH), with a price target of $28. The company’s shares closed on Friday at $23.70, close to its 52-week high of $24.15.
According to TipRanks.com, Hooker is a 5-star analyst with an average return of 15.7% and a 75.2% success rate. Hooker covers the Services sector, focusing on stocks such as Quest Diagnostics Inc, PRA Health Sciences, and Charles River Labs.
Evolent Health has an analyst consensus of Strong Buy, with a price target consensus of $28, which is a 18.1% upside from current levels. In a report issued on August 7, Jefferies also reiterated a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
Based on Evolent Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.92 million. In comparison, last year the company had a GAAP net loss of $16.91 million.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolent Health, Inc. engages in the provision of health care delivery and payment services. Its solutions include population health management, health plan administration and third party administration, network performance management, risk adjustment, pharmacy benefit management, analytics and performance improvement, and technology and electronic medical record integration. The company was founded by Frank J. Williams, Seth B. Blackley, and Tom Peterson in August 2011 and is headquartered in Arlington, VA.
